Sydney, Australia - Novotech, the leading Asia Pacific centred biotech CRO conducted a survey of global biotech professionals, in partnership with Citeline, on their current and future clinical pipeline prospects, the main challenges of clinical trials, and perspective shifts regarding study locations.
A key finding from the report is that cost is the number one concern for 32% of respondents, followed by patient recruitment at 29%.
The report shares insights into the trends and pain points in biotech clinical trials, as companies seek to secure funding for continued and future development.
Key areas covered include:
- Modalities: current pipeline vs. future investment
- Top clinical trial operational challenges
- The role of APAC: China and Australia offer key advantages
- Clinical trial and CRO strategy success factors
The report also covers trends and industry professionals’ perceptions across therapeutic areas.
For example according to the report: “When asked about the most promising therapy type for future investment and development, CGTs took the top spot (26%), followed by mRNA (22%) and antibody therapeutics (19%).”
Novotech offers biotechs a unique and unparalleled suite of early to late-phase CRO services across the US and Europe, with a focus on Asia Pacific where the company has built a reputation for delivering high-quality expedited clinical trials.
Novotech has been benchmarked as a top 10 CRO among the world’s leading CROs, is the recipient of the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence award and the Asia-Pacific Contract Research Organization Company of the Year Award, and has signed 45 Leading Site Partnership agreements over the last 3 years.
Media contact
David James
About Novotech Novotech-CRO.com
Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech companies to accelerate the development of advanced and novel therapeutics at every phase.
Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.
The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.
For more information or to speak to an expert team member visit www.Novotech-CRO.com